141 related articles for article (PubMed ID: 141906)
21. [Clinical evaluation of neocarzinostatin in digestive system cancer. 2. Clinical studies on the administration of neocarzinostatin in advanced and recurrent carcinoma of the pancreas].
Kikuchi K; Kusama S; Furue H; Muto T; Toriyama K; Wakiya M
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1872-7. PubMed ID: 6224466
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of neocarzinostatin in digestive system cancer. 1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach].
Kikuchi K; Kusama S; Furue H; Muto T; Toriyama K; Wakiya M
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1866-71. PubMed ID: 6224465
[TBL] [Abstract][Full Text] [Related]
23. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics].
Matsumura Y; Oda T; Maeda H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):821-9. PubMed ID: 2952066
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of cytotoxicity of zinostatin under acidic conditions in vitro and in vivo.
Kuroiwa T; Taniguchi S; Aoki K; Hasuda K; Baba T
Cancer Treat Rep; 1987 Mar; 71(3):247-51. PubMed ID: 2949830
[TBL] [Abstract][Full Text] [Related]
25. Neocarzinostatin: selective tryptophan oxidation and neocarzinostatin-chromophore binding to apo-neocarzinostatin.
Edo K; Saito K; Matsuda Y; Akiyama-Murai Y; Mizugaki M; Koide Y; Ishida N
Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):170-6. PubMed ID: 1828722
[TBL] [Abstract][Full Text] [Related]
26. Degradation of neocarzinostatin by blood sera in vitro and its inhibition by diisopropyl fluorophosphate and n-ethylmaleimide.
Maeda H; Takeshita J
Gan; 1975 Oct; 66(5):523-7. PubMed ID: 130275
[TBL] [Abstract][Full Text] [Related]
27. [Screening for the antagonizing agents against lethal toxicity of neocarzinostatin. I. Inhibitory effects of various drugs on the toxicity of neocarzinostatin in vitro and in vivo].
Ito A; Koide Y; Haneda I; Toriyama K; Ouchi M; Matsumoto T; Baba T
Jpn J Antibiot; 1985 Jan; 38(1):137-44. PubMed ID: 3157807
[TBL] [Abstract][Full Text] [Related]
28. [Reductive effect on ascites, of neocarzinostatin in patients with ovarian cancer].
Takahashi K; Watanabe M; Kikuchi J; Kishi H; Saito K; Mouri H; Ikeno N; Endo H; Shima I; Morizuka T
Gan To Kagaku Ryoho; 1988 May; 15(5):1777-81. PubMed ID: 2967052
[TBL] [Abstract][Full Text] [Related]
29. Neocarzinostatin in cancer chemotherapy (review).
Maeda H
Anticancer Res; 1981; 1(3):175-86. PubMed ID: 6211130
[TBL] [Abstract][Full Text] [Related]
30. Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma.
Otsuji E; Takahashi T; Yamaguchi T; Yamaguchi N; Imanishi J
Gastroenterol Jpn; 1990 Apr; 25(2):244-8. PubMed ID: 2140808
[TBL] [Abstract][Full Text] [Related]
31. Gamma-radiolysis study of the reductive activation of neocarzinostatin by the carboxyl radical.
Favaudon V
Biochimie; 1983; 65(11-12):593-607. PubMed ID: 6231960
[TBL] [Abstract][Full Text] [Related]
32. Absence of anti-neocarzinostatin (NCS) antibody production in leukemia patients treated with NCS.
Toki H
Acta Med Okayama; 1976 Apr; 30(2):135-42. PubMed ID: 135485
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration.
Sakamoto S; Ogata J; Ikegami K; Maeda H
Eur J Cancer (1965); 1980 Jan; 16(1):103-13. PubMed ID: 6444585
[No Abstract] [Full Text] [Related]
34. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer.
Oda T; Maeda H
Cancer Res; 1987 Jun; 47(12):3206-11. PubMed ID: 2953411
[TBL] [Abstract][Full Text] [Related]
35. [Fundamental studies on intravesical instillation of 4'-epi-adriamycin for the treatment of bladder cancer].
Tsushima T
Hinyokika Kiyo; 1985 Nov; 31(11):1945-56. PubMed ID: 3867286
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacokinetics of neocarzinostatin in patients with malignant glioma. Quantitative analysis of tissue concentration].
Otsuka T; Matsukado Y; Uemura S; Kuratsu J; Sonoda H; Mihara Y; Goto S
Neurol Med Chir (Tokyo); 1989 Jun; 29(6):471-5. PubMed ID: 2479848
[TBL] [Abstract][Full Text] [Related]
37. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH.
Oda T; Sato F; Maeda H
J Natl Cancer Inst; 1987 Dec; 79(6):1205-11. PubMed ID: 2961908
[TBL] [Abstract][Full Text] [Related]
38. [Neocarzinostatin: molecular mechanism of action and prospects for clinical use].
Köhnlein W; Jung G
Arzneimittelforschung; 1982; 32(11):1474-9. PubMed ID: 6217819
[TBL] [Abstract][Full Text] [Related]
39. In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin.
Lazarus H; Raso V; Samy TS
Cancer Res; 1977 Oct; 37(10):3731-6. PubMed ID: 143343
[TBL] [Abstract][Full Text] [Related]
40. [Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma].
Ohmori H; Tsushima T; Kobashi K
Gan To Kagaku Ryoho; 1996 Apr; 23(5):601-6. PubMed ID: 8678519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
